NCT06399666 Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation
| NCT ID | NCT06399666 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vrinnevi Hospital |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 182 participants |
| Start Date | 2023-10-30 |
| Primary Completion | 2025-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 182 participants in total. It began in 2023-10-30 with a primary completion date of 2025-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Because of the high recurrence rates following electrical cardioversion and high morbidity in AF patients there is a need to explore prediction models for AF recurrence following ECV. Previous studies have primarily focused on high-sensitivity CRP (hsCRP), CRP, and IL-6, while other inflammatory indexes and gene scores might hold greater value. This prospective cohort study is planning to include 182 patients with persistent atrial fibrillation, planned for electrical cardioversion, and \>18 years at two medium-sized hospitals in Sweden. Blood samples will be collected prior to electrical cardioversion and at 7-, 30-, 90-, and 180-days follow-up. Atrial fibrillation recurrence will be evaluated at follow-up or upon patient request and diagnosed with 12-lead ECG. An interim analysis will be conducted after more than 80 patients have been included. If the results from univariate and/or multivariable logistic regression on inflammatory markers and genetic expression regarding atrial fibrillation recurrence are significant, the study will be concluded.
Eligibility Criteria
Inclusion Criteria: * Persistent atrial fibrillation (ICD-10 I48.1) * Age over 18 years Exclusion Criteria: * Autoimmune disease * Inflammatory diseases * Acute or chronic liver dysfunction * Ongoing infectious diseases * Thyroid disorders * Any other conditions known to impact inflammatory activity (including medication use and hematological diseases)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06399666 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06399666 currently recruiting?
Yes, NCT06399666 is actively recruiting participants. Contact the research team at jakob.hytting@liu.se for enrollment information.
Where is the NCT06399666 trial being conducted?
This trial is being conducted at Jönköping, Sweden, Norrköping, Sweden.
Who is sponsoring the NCT06399666 clinical trial?
NCT06399666 is sponsored by Vrinnevi Hospital. The trial plans to enroll 182 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.